by Biological Sciences
Hoda Hatoum (BioMed, ICC-BDH) will present Thursday (Sept. 16) at 3 p.m. as part of the Biological Sciences Seminar Series. The presentation will be held virtually on Zoom.
From the abstract: Transcatheter aortic valve replacement (TAVR) is a non-invasive valve replacement therapy that has been recently FDA approved for low-risk patients. Despite the importance of this therapy, TAVR has been associated with several adverse effects and long-term adverse outcomes such as short durability and thrombus formation. Several clinical studies showed that the incidence of leaflet thrombosis (LT) post-TAVR ranges between 8 to 24% overall, with increasing incidences from 30 day to 1-year timepoints, which makes leaflet thrombosis a highly important concern. … The purpose of this study is to present a semi-empirical, mathematical model that links patient-specific anatomic, valve, and flow parameters to predict leaflet thrombosis. This tool will be essential in clinical pre-procedural planning. To this end, we used a combination of experimental, analytical, and computational fluid dynamic studies along with patient-specific data.